Compositions containing tigoranel for controlling parasites - Patents.com
The composition of tigolaner, praziquantel, and emodepside in 1,2-isopropylidene glycerol solvent addresses the challenges of parasitic treatments by providing long-term efficacy against internal and external parasites with improved solubility and tolerability, suitable for spot-on application.
Patent Information
- Application Number
- JP2022509052
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-08-14
- Filing Date
- 2020-08-12
- Publication Date
- 2024-12-09
- Estimated Expiration
- 2040-08-12
AI Technical Summary
There is a need for new compositions that address the challenges of activity level, duration of action, spectrum of action, toxicity, combination of active compounds, and formulation auxiliaries in parasitic treatments, while also considering the potential for resistance development and the desire for simple external application methods.
A composition comprising tigolaner, optionally with praziquantel and emodepside, using 1,2-isopropylidene glycerol as a solvent, which provides enhanced solubility and efficacy against both internal and external parasites, including tapeworms, flukes, nematodes, and mites, with a preferred application method as a spot-on treatment.
The composition achieves long-term efficacy against a wide range of parasites with minimal adverse effects, allowing for economical and convenient animal husbandry by targeting systemic and external parasites with improved solubility and tolerability.
Smart Images

Figure 0007596359000001 
Figure 0007596359000002 
Figure 0007596359000003
Abstract
Description
[Technical field]
[0001] The present invention relates to compositions comprising tigolaner, and optionally an endoparasiticide, to methods for their preparation, and to their use as drugs for controlling parasites. [Background technology]
[0002] Formulations for controlling ectoparasites in pets such as cats can be administered in so-called spot-on formulations. Spot-on treatments can be packaged as individual doses of liquid and are typically applied to the pet's back, for example by pouring the liquid between the shoulders. From there, the active agent can be absorbed into the pet's tissue and / or distributed across the pet's skin and act accordingly.
[0003] Patent document 1 discloses a composition for controlling animal parasites, comprising fipronil, flumethrin, an aliphatic cyclic carbonate, and an aliphatic cyclic or acyclic polyether. Patent document 2 is directed to a composition of matter comprising: a) 0.1-60% by weight of an active pyrethroid compound; b) 7.5-30.0% by weight of dinotefuran and / or a dinotefuran analogue; c) 27.5-62.5% by weight of an organic solvent from the classes of methylpyrrolidone, aliphatic alcohols and cyclic carbonates, aliphatic, cyclic, or acyclic ethers, and mixtures thereof; d) 0-5% by weight of water; e) 0-0.5% by weight of a phenolic antioxidant; and g) 0-0.5% by weight of an organic acid.
[0004] Emodepside (cyclo(R)-lactoyl-N-methyl-L-leucyl-(R)-3-(p-morpholinophenyl) lactoyl-N-methyl-L-leucyl-(R)-lactoyl-N-methyl-L-leucyl-(R)-3-(p-morpholinophenyl) lactoyl-N-methyl-L-leucyl) is an effective anthelmintic against several gastrointestinal nematodes. Its molecular structure, shown below, can be described as a cyclic octadepsipeptide, a depsipeptide being a peptide in which one or more of its amide groups have been replaced by the corresponding ester group. On a technical scale, emodepside can be obtained by derivatization of the natural substance PF1022A, in which two hydrogen atoms are exchanged with a morpholine ring.
[0005] [ka]
[0006] Patent Document 3 (Patent Document 4) discloses a compound having the general formula:
[0007] [ka]
[0008] wherein A is a benzyl group having suitable substituent(s) or a phenyl group which may have suitable substituent(s); Aa is a benzyl group having suitable substituent(s) or a phenyl group which may have suitable substituent(s); B and D are each lower alkyl; and C is hydrogen or lower alkyl, and pharma- ceutically acceptable salts thereof.
[0009] US Patent No. 5,399,633 relates to the use of praziquantel and epsiprantel to enhance the endoparasiticidal activity of cyclic depsipeptides in endoparasiticidal compositions.
[0010] Patent document 6 relates to transdermally administrable compositions containing cyclic depsipeptides, their preparations, and their use for controlling endoparasites. In the compositions according to this patent application, the active compounds can also be present in mixtures with synergists or other compounds that are active against pathogenic endoparasites. Examples of such active compounds include L-2,3,5,6-tetra-hydro-6-phenylimidazothiazole, benzimidazole carbamates such as febantel, as well as pyrantel, praziquantel, and ivermectin.
[0011] US Pat. No. 5,399,633 relates to topical compositions comprising emodepside and praziquantel or epsiprantel and 1,2-isopropylideneglycerol, their preparations and their use for controlling internal parasites.
[0012] Praziquantel and epsiprantel have the following structures:
[0013] [ka]
[0014] Antiparasitic products for animals are commercially available under the name Profender®. These include Profender® spot-on solution for cats, which contains emodepside and praziquantel as active ingredients, and butylated hydroxyanisole, isopropylideneglycerol and lactic acid as excipients.
[0015] Tigolaner (Non-Patent Document 1) is an antiparasitic drug for veterinary use having the following structure:
[0016] [ka]
[0017] Tigoraner is described in structure Ic-2, table 3 of US Patent No. 8,363,666. By way of example, Tigoraner is also mentioned in Example 3 (page 39) of US Patent No. 8,363,666. International patent applications relating to the synthesis of such compounds are, for example, US Patent No. 8,363,666, US Patent No. 8,363,666, US Patent No. 8,363,666, and US Patent No. 8,363,666. [Prior art documents] [Patent documents]
[0018] [Patent Document 1] International Publication No. 2008 / 080542 [Patent Document 2] International Publication No. 2005 / 105034 [Patent Document 3] WO 93 / 19053 [Patent Document 4] European Patent Application Publication No. 0634408 [Patent Document 5] European Patent Application Publication No. 0662326 [Patent Document 6] US Patent Application Publication No. 2003 / 125244 [Patent Document 7] US Patent Application Publication No. 2008 / 255037 [Patent Document 8] International Publication No. 2014 / 122083 [Patent Document 9] International Publication No. 2016 / 177619 [Patent Document 10] International Publication No. 2014 / 012975 [Patent Document 11] International Publication No. 2015 / 078846 [Patent Document 12] International Publication No. 2015 / 078847 [Patent Document 13] International Publication No. 2015 / 150302 [Patent Document 14] International Publication No. 2015 / 181139 [Patent Document 15] International Publication No. 2016 / 026789 [Non-patent literature]
[0019] [Non-Patent Document 1] WHO Drug Information,Vol.31,No.2,2017,p.341 Summary of the Invention [Problem to be solved by the invention]
[0020] Due to the wide variety of requirements that must be met by modern medicines, e.g. activity level (e.g. plasma concentration of the active compound), duration of action, spectrum of action, scope of application, toxicity, combination of active compounds, combination with formulation auxiliaries, and also due to the possibility of resistance developing, the development of new medicines can never be considered complete and at least some In certain aspects, there is a continuing need for new compositions that offer advantages over known compositions.
[0021] In order to enable pet owners to apply the parasiticidal active compounds in the simplest possible way, it is further desirable to provide compositions which can be applied topically, where topical application in the context of this application generally means application to the skin or hair of the animal.
[0022] Such compositions include, for example: -Efficacy (especially if the active compound acts systemically) -Safety of the target animals, safety of the users - Well tolerated - Additional criteria must be met, such as convenience. [Means for solving the problem]
[0023] The present invention is directed to a composition according to claim 1 and in further embodiments to a composition according to claim 5, a method according to claim 14, a composition for use as a medicament according to claim 15 and a composition for use in the treatment and / or prevention of parasitic infections in animals according to claim 16. Advantageous embodiments are the subject of the dependent claims. They can be freely combined unless the context clearly dictates otherwise. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0024] Thus, one embodiment of the present invention is a composition comprising tigolaner and 1,2-isopropylideneglycerol. The composition may preferably comprise tigolaner in an amount of 1% to 15% by weight, and according to a further preferred embodiment, the composition may comprise tigolaner in an amount of 1% to 11% by weight, or 7% to 11% by weight, or 1% to 9.5% by weight, or 7% to 9.5% by weight. The composition optionally further comprises praziquantel, preferably in a concentration of 1% to 15% by weight (preferably 6% to 9% by weight). In compositions according to the present invention containing tigolaner and solketal but not praziquantel, the amount of tigolaner is preferably less than 10% by weight, more preferably less than 9.5% by weight.
[0025] According to a further embodiment, the present invention includes a composition comprising praziquantel, emodepside and a solvent component, further comprising tigoranel. These substances have the structure already defined in the previous section. The composition according to this embodiment expands the endoparasiticidal action of praziquantel and emodepside with the ectoparasiticidal action of tigoranel. In particular, it can control tapeworms, trematodes, nematodes, ancynocephalanxes and mites.
[0026] Unless otherwise specified, the solvent component preferably contains a solvent suitable for transdermal application of an active pharmaceutical ingredient, such as DMSO, NMP, 2-pyrrolidone, dimethylacetamide (DMAc), glycerin formal (also called glycerol form), tetraglycol, triethyl phosphate, propylene carbonate, or 1,2-isopropylideneglycerol (also known as solketal).
[0027] The control of pathogenic internal parasites is intended to reduce disease, mortality and loss of performance (e.g. in the production of meat, milk, wool, leather, eggs, honey, etc.) and the use of active compounds allows for more economical and simpler animal rearing. Pathogenic internal parasites include cestodes, trematodes, nematodes and anchocephalus.
[0028] Praziquantel specifically controls the following internal parasites: From the order Pseudophyllidea, for example, Diphyllobothrium spp., Spirometra spp., Schistocephalus spp., Ligula spp., Bothridium spp., Diphlogonoporus spp.; From the order of Cyclophyllidea, for example, Mesocestoides spp., Anoplocephala spp., Paranoplocephala spp., Moniezia spp., Thysanosomsa spp., Thysaniezia spp., Avitellina spp., Stilesia spp., Cittotaenia spp., Andyra spp., Bertiella spp., Taenia spp., Echinococcus spp., Hydatigera spp., Davainea spp., Raillietina spp., Hymenolepis spp., Echinolepis spp., Echinocotyle spp., Diorchis spp., Dipylidium spp., Joyuxiella spp., Diplopylidium spp.;from the subclass Monogenea, e.g., Gyrodactylus spp., Dactylogyrus spp.Polystoma spp.; From the subclasses of Digenea, for example, Diplostomum spp., Posthodiplostomum spp., Schistosoma spp., Trichobilharzia spp., Ornithobilharzia spp., Austrobilharzia spp., Gigantobilharzia spp., Leucochloridium spp., Brachylaima spp., Echinostoma spp., Echinoparyphium spp., Echinochasmus spp., Hypoderaeum spp., Fasciola spp., Fasciolides spp., Fasciolopsis spp., Cyclocoelum spp., Typhlocoelum spp., Paramphistomum spp., Calicophoron spp., Cotylophoron spp., Gigantocotyle spp., Fischoederius spp., Gastrothylacus spp., Notocotylus spp., Catatropis spp., Plagiorchis spp., Prosthogonimus spp., Dicrocoelium spp., Eurytrema spp., Troglotrema spp., Paragonimus spp., Collyriclum spp., Nanophyetus spp., Opisthorchis spp., Clonorchis spp.Metorchis spp., Heterophyes spp., Metagonimus spp.
[0029] Emodepsids specifically control the following internal parasites: From the order Enoplida, e.g., Trichuris spp., Capillaria spp., Trichomosoides spp., Trichinella spp.; From the order Rhabditia, for example, Micronema spp., Strongyloides spp., Aelurostrongylus spp., Troglostrongylus brevior; From the order Strongylida, for example, Stronylus spp., Triodontophorus spp., Oesophagodontus spp., Trichonema spp., Gyalocephalus spp., Cylindropharynx spp., Poteriostomum spp., Cyclococercus spp., Cylicostephanus spp., Oesophagostomum spp., Chabertia spp., Stephanurus spp., Ancylostoma spp., Uncinaria spp., Bunostomum spp.; Globocephalus spp., Syngamus spp., Cyathostoma spp., Metastrongylus spp., Dictyocaulus spp., Muellerius spp., Protostrongylus spp., Neostrongylus spp., Cystocaulus spp., Pneumostrongylus spp., Spicocaulus spp., Elaphostrongylus spp., Parelaphostrongylus spp., Crenosoma spp., Paracrenosoma spp., Angiostrongylus spp., Aelurostrongylus spp., Filaroides spp., Parafilaroides spp., Trichostrongylus spp., Haemonchus spp., Ostertagia spp., Marshallagia spp., Cooperia spp., Nematodirus spp., Hyostrongylus spp., Obeliscoides spp., Amidostomum spp., Ollulanus spp.; From the order Oxyurida, e.g., Oxyuris spp., Enterobius spp., Passalurus spp., Syphacia spp., Aspiculuris spp., Heterakis spp.; From the order Ascaridia, e.g., Ascaris spp., Toxascaris spp., Toxocara spp., Parascaris spp., Anisakis spp., Ascaridia spp.; From the order Spirurida, for example, Gnathostoma spp., Physaloptera spp., Thelazia spp., Gongylonema spp., Habronema spp., Parabronema spp., Draschia spp., Dracunculus spp.; From the order Filariida, for example, Stephanofilaria spp., Parafilaria spp., Setaria spp., Loa spp., Dirofilaria spp., Litomosoides spp., Brugia spp., Wuchereria spp., Onchocerca spp.; From the order Gigantorhynchida, for example, Filicollis spp., Moniliformis spp., Macracanthorhynchus spp., Prosthenorchis spp.
[0030] Pests targeted by Tigoranelle include: From the order Anoplura, e.g., aematopinus spp., Linognathus spp., Solenopotes spp., Pediculus spp., Pthirus spp.; From the order Mallophaga, for example, Trimenopon spp., Menopon spp., Eomena¬canthus spp., Menacanthus spp., Trichodectes spp., Felicola spp., Damalinea spp., Bovicola spp.; From the suborder Brachycera of the order Diptera, for example, Chrysops spp., Tabanus spp., Musca spp., Hydrotaea spp., Muscina spp., Haematobosca spp., Haematobia spp., Stomoxys spp., Fan¬nia spp., Glossina spp., Lucilia spp., Calliphora spp., Auchmeromyia spp., Cordylobia spp., Cochliomyia spp., Chrysomyia spp., Sarcophaga spp., Wohlfartia spp., Gasterophilus spp., Oesteromyia spp., Oedemagena spp., Hypo¬derma spp., Oestrus spp., Rhinoestrus spp., Melop hagus spp., Hippobosca spp.; From the suborder Nematocera of the order Diptera, for example, Culex spp., Aedes spp., Anopheles spp., Culicoides spp., Phlebotomus spp., Simulium spp.; From the order Siphonaptera, for example, Ctenocephalides spp., Echidnophaga spp., Ceratophyllus spp., Pulex spp.; From the order Metastigmata, for example, Hyalomma spp., Rhipicephalus spp., Boophilus spp., Amblyomma spp., Haemaphysalis spp., Dermacentor spp., Ixodes spp., Argas spp., Ornithodorus spp., Otobius spp.; From the order Mesostigmata, e.g., Dermanyssus spp., Ornithonyssus spp., Pneumonyssus spp.; From the order Prostigmata, for example, Cheyletiella spp., Psorergates spp., Myobia spp., Demodex spp., Neotrombicula spp.; From the order Astigmata, for example, Acarus spp., Myocoptes spp., Psoroptes spp., Chorioptes spp., Otodectes spp., Sarcoptes spp., Notoedres spp., Knemidocoptes spp., Neoknemidocoptes spp., Cytodites spp., Laminosioptes spp.
[0031] Fleas (Siphonaptera, e.g. Ctenocephalides spp., Echidnophaga spp., Ceratophyllus spp., Pulex spp.), ticks (Hyalomma spp., Rhipicephalus spp., Boophilus spp., Amblyomma spp., Haemaphysalis spp., Dermacentor spp., Ixodes spp., Argas spp., Ornithodorus spp., Otobius spp.), and the above Diptera (C Chrysops spp., Tabanus spp., Musca spp., Hydrotaea spp., Muscina spp., Haematobosca spp., Haematobia spp., Stomoxys spp., Fannia spp., Glossina spp., Lucilia spp., Calliphora spp., Auchmeromyia spp., Cordylobia spp., Cochliomyia spp., Chrysomyia spp., Sarcophaga spp., Wohlfartia spp., Gasterophilus spp., Oesteromyia spp., Oedemagena spp., Hypoderma spp., Oestrus spp., Rhinoestrus spp., Melophagus spp., Hippobosca spp.) may be of particular importance.
[0032] In one embodiment of the composition, the solvent component comprises 1,2-isopropylideneglycerol and the water content of the composition is at most 5% by weight, preferably at most 3% by weight, more preferably at most 2% by weight, even more preferably at most 1.5% by weight, in particular at most 1% by weight.
[0033] In another embodiment of the composition, the solvent component comprises only 1,2-isopropylideneglycerol. The solubility of tigolaner in solketal alone has been determined to be in the range of about 9.5-9.9% w / w. Surprisingly, it has been found that in the presence of praziquantel, particularly 7.5-8.5% w / w praziquantel, the solubility can be increased to more than 10.5% w / w in solketal.
[0034] In another embodiment, the composition comprises: 1% by weight or more and 15% by weight or less (preferably 6% by weight or more and 9% by weight or less) of praziquantel; 1% by weight or more and 10% by weight or less (preferably 1.2% by weight or more and 3% by weight or less) of emodepside; and 1% by weight or more and 15% by weight or less (preferably 7% by weight or more and 11% by weight or less) of tigoranel, The weight percentages are based on the total weight of the composition.
[0035] Preferably, the composition comprises: 1% by weight or more and 15% by weight or less (preferably 6% by weight or more and 9% by weight or less) of praziquantel; 1% by weight or more and 10% by weight or less (preferably 1.2% by weight or more and 3% by weight or less) of emodepside; 1% by weight or more and 15% by weight or less (preferably 7% by weight or more and 11% by weight or less) of tigoranel; and 0% by weight or more and 5% by weight or less (preferably 1% by weight or more and 3% by weight or less) of other components excluding the solvent, The weight percentages are based on the total weight of the composition, with the remainder to 100% by weight being made up by 1,2-isopropylideneglycerol as the solvent component.
[0036] In another embodiment, the composition further comprises an antioxidant, which is capable of, inter alia, protecting praziquantel and / or emodepside from oxidation.
[0037] In another embodiment, the antioxidant is butyl hydroxyanisole (BHA) and / or butyl hydroxytoluene (BHT).Preferably, the composition of the present invention contains BHT.According to another preferred embodiment, the composition of the present invention contains BHA and BBHT.
[0038] In another embodiment, the composition further comprises an acid. These acids are preferably carboxylic acids. They may act as stabilizers.
[0039] In another embodiment, the acid is lactic acid.
[0040] In another embodiment, the composition comprises: 1% by weight or more and 15% by weight or less (preferably 6% by weight or more and 9% by weight or less) of praziquantel; 1% by weight or more and 10% by weight or less (preferably 1.2% by weight or more and 3% by weight or less) of emodepside; 1% by weight or more and 15% by weight or less (preferably 7% by weight or more and 11% by weight or less) of tigoranel; 0.01% by weight or more and 1% by weight or less (preferably 0.1% by weight or more and 0.5% by weight or less) of butylhydroxyanisole (BHA) and / or butylhydroxytoluene (BHT); 1% by weight or more and 5% by weight or less (preferably 1.5% by weight or more and 2.5% by weight or less) of lactic acid, The weight percentages are based on the total weight of the composition.
[0041] Preferably, the composition comprises: 1% by weight or more and 15% by weight or less (preferably 6% by weight or more and 9% by weight or less) of praziquantel; 1% by weight or more and 10% by weight or less (preferably 1.2% by weight or more and 3% by weight or less) of emodepside; 1% by weight or more and 15% by weight or less (preferably 7% by weight or more and 11% by weight or less) of tigoranel; 0.01% by weight or more and 1% by weight or less (preferably 0.1% by weight or more and 0.5% by weight or less) of butylhydroxyanisole (BHA) and / or butylhydroxytoluene (BHT); 1% by weight or more and 5% by weight or less (preferably 1.5% by weight or more and 2.5% by weight or less) of lactic acid, The weight percentages are based on the total weight of the composition, with the remainder to 100% by weight being made up by 1,2-isopropylideneglycerol as the solvent component.
[0042] The presence of lactic acid slightly reduces the solubility of tigolaner in 1,2-isopropylideneglycerol. Therefore, compositions containing tigolaner and 1,2-isopropylideneglycerol should contain low concentrations of lactic acid, i.e. It is preferable to use lactic acid at 1% by weight or more and 3% by weight or less (preferably 1% by weight or more and 2.5% by weight or less).
[0043] The present invention is also directed to a method for producing a composition according to the invention, comprising dissolving the active ingredient or ingredients, and optionally further ingredients, in a solvent component. According to one embodiment, the method comprises dissolving praziquantel, emodepside and tigolanel in the solvent component.
[0044] The compositions are prepared by mixing the appropriate amounts of the ingredients in a suitable container; preferably, the ingredients are mixed until a clear solution is formed.
[0045] According to one embodiment, in a composition containing emodepside and tigoranel, the emodepside can be added before the tigoranel to facilitate dissolution of the tigoranel.
[0046] According to a further embodiment, in a composition containing praziquantel, emodepside and tigoraner, the praziquantel and emodepside can be added before the tigoraner to facilitate dissolution of the tigoraner.
[0047] To speed up the dissolution rate, the mixture can be heated and / or subjected to shear forces.
[0048] The preparation of the compositions of the present invention can be carried out under an inert gas, preferably a dry inert gas, for example by blanketing with nitrogen or argon. "Dry" inert gas preferably means that the gas contains less than 100 ppm (by volume) of water.
[0049] In general, it has proven advantageous to meter the compositions according to the invention so that about 1 to about 100 mg of the active compound per kg of body weight is administered per application. Preference is given in the case of emodepside to 1 to 20 mg, in particular 1 to 10 mg, of active compound per kg of body weight, in the case of praziquantel to 5 to 50 mg, in particular 5 to 20 mg, of active compound per kg of body weight, and in the case of tigolaner to 5 to 30 mg, in particular 10 to 20 mg, of active compound per kg of body weight.
[0050] A further aspect of the invention is a composition according to the invention for use as a medicament.
[0051] Without being bound by any theory, it is believed that tigolaner acts primarily systemically, i.e., penetrates the skin and enters the blood circulation. Emodepside and praziquantel are also believed to act systemically because they act against internal parasites.
[0052] The application can be both prophylactic and therapeutic.
[0053] Preferably, the composition according to the present invention is suitable for application by spot-on, pour-on or spraying, for example, spray application can be carried out using pump spray or aerosol spray (pressurized spray).For certain applications, the formulation can also be used as a dip agent after diluting with water, in which case the formulation should contain emulsifying additives.
[0054] Preferred application forms are pump spray, pour-on and spot-on, application by spot-on being very particularly preferred.
[0055] The present invention also includes a composition according to the invention for use in the treatment and / or prevention of a parasitic infection in an animal.
[0056] The animal is preferably a mammal, such as, for example, a cat, dog or ferret.
[0057] In one embodiment, the animal is a cat.
[0058] In another embodiment, the parasites are endoparasites and ectoparasites.
[0059] In another embodiment, the parasite is endoparasites selected from Toxocara cati, Toxascaris leonina, Ancylostoma tubaeforme, Uncinaria stenocephala, Dipylidium caninum, Taenia taeniaeformis, Echinococcus multiocularis, Aelurostrongylus abstrusus, and Troglostrongylus spp.; Ectoparasites selected from Ctenocephalides spp., Echidnophaga spp., Cteratophyllus spp., Pulex spp., Hyalomma spp., Rhipicephalus spp., Boophilus spp., Amblyomma spp., Haemaphysalis spp., Dermacentor spp., Ixodes spp., Argas spp., Ornithodorus spp., Otobius spp., Otodectes cynotis, Notoedres cati, and combinations thereof.
[0060] Tigolaner exhibits long-term efficacy, and therefore the compositions of the present invention may be applied to the host animal at intervals of 4 weeks or more, preferably 8 weeks or more, more preferably 10 weeks or more, especially 12 weeks or more. EXAMPLES
[0061] The present invention is further described in the following examples, without wishing to be limited thereby. Solketal is 1,2-isopropylidene glycerol. All examples shown include Solketal that already contains 0.3% BHA for general solvent stability.
[0062] The examples were prepared by mixing the components using a stirrer. In the composition containing praziquantel and tigoranel, praziquantel was added first to facilitate the dissolution of tigoranel. In the composition containing emodepside and tigoranel, the preferred option is to add emodepside first to facilitate the dissolution of tigoranel. In the composition containing praziquantel, emodepside and tigoranel, the preferred option is to add praziquantel and emodepside first to facilitate the dissolution of tigoranel. All examples are homogeneous solutions.
[0063] [Table 1]
[0064] [Table 2]
[0065] [Table 3]
[0066] [Table 4]
[0067]
Table 5
[0068]
Table 6
[0069]
Table 7
[0070]
Table 8
[0071]
Table 9
[0072]
Table 10
[0073]
Table 11
[0074]
Table 12
[0075]
Table 13
[0076]
Table 14
[0077]
Table 15
[0078]
Table 16
[0079]
Table 17
[0080]
Table 18
[0081]
Table 19
[0082]
Table 20
[0083]
Table 21
[0084]
Table 22
[0085]
Table 23
[0086]
Table 24
[0087]
Table 25
[0088] Biological Examples A. Summary of in vitro test results of Tigoraner disclosed in Patent Document 7 The test methods and results have already been described in US Pat. No. 5,999,633. The results disclosed for Tigolaner (Example Ic-2 of US Pat. No. 5,999,633) for parasites relevant in the veterinary field are summarized below: Amblyomma hebraeum: 100% effective at 100 ppm Boophilus microplus - Immersion test: 100% effective at 100 ppm Boophilus microplus - Injection test: 100% effective at 20 μg / mite Ctenocephalides felis - Oral test: 100% effective at 100ppm Ctenocephalides felis - Contact test: 100% efficacy at 1μg / cm2 Lucilia cuprina: 100% effective at 100ppm Musca domestica: 100% effectiveness at 100 ppm Ripicephalus sanguineus - Contact test: 100% efficacy at 1μg / cm2 Ixodes ricinus - Contact test: 100% efficacy at 1μg / cm2 Amblyomma hebraeum - Contact test: 100% efficacy at 1μg / cm2
[0089] B. Summary of in vivo test results of Tigoraner in rats, as disclosed in US Pat. No. 6,399,663 The test methods and results have already been described in US Pat. No. 6,399,663. The results of Tigoraner (Example Ic-2 of US Pat. No. 6,399,663) for parasites relevant in the veterinary field are summarized below: Dermacentor variabilis - Systemic in vivo activity against American dog tick nymphs in rats: >90% efficacy against tick nymphs on day 2 at an applied dose of 10 mg / kg.
[0090] Ctenocephalides felis - A systemic inhibitor of fleas in rats In vivo activity: >95% efficacy on day 2 and >90% efficacy on day 9 at a dose of 10 mg / kg.
[0091] C. Internal parasites in vivo testing: Efficacy of spot-on formulations against patent infections of Toxocara cati and Dipylidium caninum in experimentally infected cats. Prior to treatment, 16 cats were experimentally infected with T. cati (larval eggs) and D. caninum felidae using infected C. felis fleas (oral and topical infection), respectively.
[0092] Fourteen cats with patent infections of both T. cati and D. caninum were included in the study on Day 1. The cats were assigned to two groups of seven each.
[0093] The spot-on experimental veterinary medicinal product (IVP) was a composition according to the invention containing 10% tigolaner, 7.94% praziquantel, and 1.98% emodepside (w / v) in solution in a solketal base. The IVP was administered to cats in the IVP group (group 2) on day 0 at a dose rate of 3.2 mg emodepside plus 12.7 mg praziquantel and 16 mg tigolaner / kg BW (BW=body weight), corresponding to 0.16 mL of spot-on formulation per kg BW. The cats in group 1 served as the negative control group. On day 10, the cats were euthanized and gastrointestinal worms were collected during necropsy. The parasites were identified and counted. The efficacy calculation was based on the number of parasites collected at necropsy in the IVP group compared to the negative control group. The following formula was used: Effectiveness(%)=100x(Mc-Mt) / Mc, During the ceremony, Mc = geometric mean number of parasites / scolex in the negative control group (group 1) Mt = geometric mean number of parasites / scolex in the IVP group (group 2)
[0094] All cats in the control group contained T. cati worms, whereas five cats contained D. caninum scolex. 100% efficacy was obtained in the IVP group against both T. cati and D. caninum.
[0095] No adverse events (AEs) occurred.
[0096] D. In vivo testing of ectoparasites: Efficacy of spot-on formulations against experimental tick and flea infestations in cats. In SD-4, 12 cats were included in the study. In SD-1, cats were experimentally infested with Ixodes ricinus mites, which were not removed and counted in SD0 (for group allocation) and were removed and counted in SD2 (treatment efficacy). In SD0, six cats were treated with IVP applied once as a spot-on at a dosage of 14 mg tigolaner + 3 mg emodepside + 12 mg praziquantel per kg body weight. Six cats served as untreated controls.
[0097] The IVP contained 10% (m / V) tigolaner, 8.58% (m / V) praziquantel, and 2.14% (m / V) emodepside in solution in a solketal base.
[0098] Cats were experimentally infested with ticks and fleas every two weeks. Efficacy of the IVP was determined by comparing tick and flea counts in treated and control groups. General health was observed daily.
[0099] [Table 26]
[0100] [Table 27]
[0101] Efficacy against fleas (99% or higher) was achieved on all test dates up to SD85.
[0102] Therapeutic efficacy against mites (>90%) could be achieved at SD2, and preventive efficacy against mites could be achieved up to SD87.
[0103] IVP was very well tolerated in cats following a single topical treatment, and no adverse events were associated with IVP treatment during this study.
Claims
1. A composition for use in the treatment and / or prevention of a parasitic infection in an animal, comprising praziquantel, emodepside, tigolaner, and 1,2-isopropylideneglycerol, The parasites are endoparasites and ectoparasites; composition.
2. The composition described in claim 1, having a moisture content of up to 5% by weight.
3. 1% by weight or more and 15% by weight or less of praziquantel; 1% by weight or more and 10% by weight or less of emodepside; and 1% by weight or more and 15% by weight or less of tigoranel, 3. The composition of claim 1 or 2, wherein the weight percentages are based on the total weight of the composition and add up to a maximum of 100% by weight.
4. The composition of any one of claims 1 to 3, further comprising an antioxidant.
5. 5. The composition of claim 4, wherein the antioxidant is butylated hydroxyanisole (BHA) and / or butylated hydroxytoluene (BHT).
6. The composition of any one of claims 1 to 5, further comprising an acid.
7. The composition of claim 6 , wherein the acid is lactic acid.
8. A method for producing the composition of any one of claims 1 to 7, comprising dissolving praziquantel, emodepside, and tigoraner in 1,2-isopropylideneglycerol.
9. The parasite is endoparasites selected from Toxocara cati, Toxascaris leonina, Ancylostoma tubaeforme, Uncinaria stenocephala, Dipylidium caninum, Taenia taeniaeformis, Echinococcus multiocularis, Aelurostrongylus abstrusus, and Troglostrongylus spp.; Ctenocephalides spp. , Echidnophaga spp. , Cteratophyllus spp. , Pulex spp. , Hyalomma spp. , Rhipicephalus spp. , Boophilus spp. , Amblyomma spp. , Haemaphysalis spp. , Dermacentor spp. , Ixodes spp. , Argas spp. , Ornithodorus spp. , Otobius spp. ectoparasites selected from Otodectes cynotis, and Notoedres cati; The composition of any one of claims 1 to 7, selected from the group consisting of:
10. Use of a composition according to any one of claims 1 to 7 or 9 in the manufacture of a medicament for use in the treatment and / or prevention of parasitic infections in an animal.
Citation Information
Patent Citations
Depsipeptide derivative, production thereof and use thereof
EP0634408A1
Endoparasitical agents containing praziquantel and epsiprantel
EP0662326A2
internal parasite repellent
JP2008532959A
Parasiticidal compositions comprising multiple active agents, methods and uses thereof
JP2017036332A
Endoparasiticidal agents
US20030125244A1
